Krsnaa Diagnostics provides medical imaging and laboratory testing services primarily through long-term partnerships with government health departments and private hospitals. It operates a large network of diagnostic centers across India, earning revenue by performing tests for patients at subsidized or market rates.
The company possesses a narrow moat based on a cost and scale advantage within the Public-Private Partnership (PPP) framework. High upfront capital requirements for radiology equipment and long-term government contracts create high entry barriers, though low average ROCE (9.9%) suggests the moat is not yet translating into significant excess returns.
Management aggressively reinvests in infrastructure-heavy radiology and pathology rollouts, such as the Rajasthan project. While revenue growth is high (40% CAGR), the heavy front-ended capex has kept return ratios suppressed, and the recent shift toward retail and specialty care (Apulki) indicates a search for higher-margin cash flows.
The business collapsed under the weight of its own receivables and capital intensity. The Public-Private Partnership model proved to be a trap where the company front-loaded massive capex for radiology equipment while the government indefinitely delayed payments, leading to a liquidity crunch. As high-level executives continued to exit, operational oversight slipped, and the aggressive pivot into retail failed to generate the necessary margins to offset the 139-day collection cycle. Ultimately, the low return on capital never converged with the high growth rates, leaving the company as a capital-hungry utility with no pricing power and a depleted cash reserve.
RichFakir rates Krsnaa Diagnostics Ltd's business quality as mediocre — 42/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as narrow.
On our model, Krsnaa Diagnostics Ltd is trading about 8% above our estimate of fair value; we rate its price fair. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Krsnaa Diagnostics Ltd is: Not rated. A mediocre business at a fair price — it does not make our shortlist right now.
RichFakir's educational estimate of Krsnaa Diagnostics Ltd's fair value is about ₹467 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →